Poseida Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Poseida Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). A well-capitalized gene therapy innovator with differentiated allogeneic CAR-T technology, strong pharma partnerships, and clear path to value inflection through clinical data and regulatory milestones. P-BCMA-ALLO1 received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for relapsed/refractory multiple myeloma in Q3 2024. The company's cash flow positivity, substantial partnership revenue.
What is Poseida Therapeutics, Inc.'s industry? Poseida Therapeutics, Inc. (poseida.com) operates in Gene Therapy. AskCyborg classifies Poseida Therapeutics, Inc. under Gene Therapy in its company registry.
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T c...
Cyborg Score thesis
A well-capitalized gene therapy innovator with differentiated allogeneic CAR-T technology, strong pharma partnerships, and clear...
Read the full analyst-debate transcript →Get the Latest Poseida Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreePoseida Therapeutics, Inc. Overview
Pro stress-test →Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates. The company creates CAR-T therapies with high levels of TSCM (stem cell-derived memory T cells) for the treatment of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer.
Strategic Profile
Pro stress-test →Poseida's proprietary platforms include the piggyBac non-viral DNA delivery system and the Cas-CLOVER site-specific gene editing system for precise genetic modifications. The company generated $130 million in non-dilutive partnership-related milestones and payments in the first nine months of 2024 and was cash flow positive for that period, with partnerships including Roche and Astellas.
Competitive Landscape
Pro stress-test →Poseida competes in the allogeneic CAR-T and gene therapy market against players like Juno Therapeutics (Celgene/BMS), Caris Life Sciences, and UniQure. The company differentiates through its non-viral piggyBac DNA delivery platform and Cas-CLOVER gene editing system, enabling off-the-shelf, TSCM-rich CAR-T products. Key competitive advantages include rapid patient accessibility without bridging therapy and favorable tolerability profiles in early clinical data.
Industry Context
Poseida Therapeutics, Inc. operates in Gene Therapy.
Key facts
Founded: 2015 · Headquarters: San Diego, US · Employees: 132 · Revenue: $54.1 million (H1 2024) · Market cap: N/A